Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.79 |
| ▸ | MEN1 | O00255 | 3/20 | 0.79 |
| ▸ | MAPT | P10636 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | CA1 | P00915 | 2/20 | 0.68 |
| ▸ | CA2 | P00918 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | CA12 | O43570 | 1/20 | 0.63 |
| ▸ | CA9 | Q16790 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29591107 | 1.00 | KMT2A (0.79) | KMT2AMEN1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL248400 | 0.92 | CA1 (0.79) | KMT2AMEN1MAPTCA1CA2 | |
| SCHEMBL30738251 | 0.92 | CA1 (0.79) | KMT2AMEN1MAPTCA1CA2 | |
| SCHEMBL6380843 | 0.89 | ALDH1A1 (0.70) | KMT2AMEN1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL6802359 | 0.89 | ALDH1A1 (0.70) | KMT2AMEN1MAPTALDH1A1CA1 | |
| SCHEMBL4029338 | 0.88 | KMT2A (0.70) | KMT2AMEN1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL6376510 | 0.88 | CA1 (0.67) | KMT2AMEN1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL3546981 | 0.88 | MAPT (0.72) | KMT2AMEN1MAPTALDH1A1CA1 | |
| SCHEMBL6378503 | 0.88 | CA1 (0.74) | KMT2AMEN1ALDH1A1SMN1; SMN2CA1 | |
| SCHEMBL4023715 | 0.88 | CA1 (0.67) | KMT2AMEN1MAPTALDH1A1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058346-A1 | Novel enantiomers of etrahydroisoquinoline derivatives and theirpharmaceutically acceptable salts, their preparations and pharmaceutical compositions | YUN-CHOI HYE-SOOK | 2006-03-16 | — | — | US | claimed |
| WO-2021115413-A1 | NEUROMUSCULAR-BLOCKING DRUG AND PREPARATION METHOD THEREFOR | 江苏恒瑞医药股份有限公司 | 2021-06-17 | — | — | WO | disclosed |
| WO-2021115413-A1 | NEUROMUSCULAR-BLOCKING DRUG AND PREPARATION METHOD THEREFOR | 江苏恒瑞医药股份有限公司 | 2021-06-17 | — | — | WO | disclosed |
| EP-1611104-B1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-07-01 | — | — | EP | disclosed |
| EP-1611104-B1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-07-01 | — | — | EP | disclosed |
| US-20060178515-A1 | Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-08-10 | — | — | US | disclosed |
| US-20060058346-A1 | Novel enantiomers of etrahydroisoquinoline derivatives and theirpharmaceutically acceptable salts, their preparations and pharmaceutical compositions | YUN-CHOI HYE-SOOK | 2006-03-16 | — | — | US | disclosed |
| EP-1611104-A1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2006-01-04 | — | — | EP | disclosed |
| EP-1507764-A4 | NOVEL ENANTIOMERS OF TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS | YUN-CHOI HYE-SOOK (KR) | 2005-06-22 | — | — | EP | disclosed |
| EP-1507764-A1 | NOVEL ENANTIOMERS OF TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS | Yun-Choi, Hye-Sook (KR) | 2005-02-23 | — | — | EP | disclosed |
| EP-1274687-B1 | 1,2,3,4- TETRAHYDROISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2005-01-05 | — | — | EP | disclosed |
| WO-2004085403-A1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004085403-A1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-10-07 | — | — | WO | disclosed |
| US-6703392-B2 | OREXIN RECEPTOR ANTAGONISTS FOR OBESITY OR SLEEPING DISORDER TREATMENT | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-03-09 | — | — | US | disclosed |
| WO-2003095426-A1 | NOVEL ENANTIOMERS OF TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS | YUN-CHOI HYE-SOOK (KR) | 2003-11-20 | — | — | WO | disclosed |
| US-20030176415-A1 | 1,2,3,4-tetrahydroisoquinoline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2003-09-18 | — | — | US | disclosed |
| EP-1274687-A1 | 1,2,3,4- TETRAHYDROISOQUINOLINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001068609-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058346-A1 | Novel enantiomers of etrahydroisoquinoline derivatives and theirpharmaceutically acceptable salts, their preparations and pharmaceutical compositions | TBXA2R, NOS2, TBXAS1 | KMT2A 3931/4885MEN1 4467/4885MAPT 4502/4885 |
| US-20060178515-A1 | Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists | HCRTR2, HCRTR1, OXTR | KMT2A 1035/4885MEN1 1135/4885MAPT 2015/4885 |
| US-20030176415-A1 | 1,2,3,4-tetrahydroisoquinoline derivatives | HCRTR2, HCRTR1, NPY2R | KMT2A 1396/4885MEN1 764/4885MAPT 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.